Grilled Cheese

ExploreLog inSign up
Terms of UsePrivacy PolicyCommunity StandardsHelpGet the app

Grilled Cheese is a product of Village Compute

Version devBuilt at: 2026-10-10 01:38:52 EDT

Explore

PostsPeople
LatestRanked
@sodatroubles.bsky.socialOct 10, 2026, 3:30 AM

Persistent Hypophosphatemia in Gitelman Syndrome: A Cohort Study on Prevalence and Associated Factors
#nephsky #nephrology
www.kidneymedicinejournal.org/article/S259...

@aspneph.bsky.socialOct 9, 2026, 8:00 PM

Left ventricular remodeling by cardiac magnetic resonance in children with advanced chronic kidney disease: an analysis of the Chronic Kidney Disease in Children (CKiD) study
#openaccess
#nephsky

buff.ly/u7SDj5L

@aspneph.bsky.socialOct 9, 2026, 5:00 PM

The incidence and risk factors associated with severe acute kidney injury and operative mortality in neonates following cardiac surgery: a single-center experience
#nephsky

buff.ly/YhmyXuZ

@nkf-professionals.bsky.socialOct 9, 2026, 4:03 PM

There’s always more to learn in kidney care 🤓 Stay connected to continuing education designed for kidney health professionals through NKF’s PERC: www.kidney.org/education

#Nephrology #MedEd #NephSky

@sodatroubles.bsky.socialOct 9, 2026, 3:19 AM

High urine osmolality and elevated urine sodium predict early nonresponse to fluid restriction in patients with the syndrome of inappropriate antidiuresis
#nephsky #nephrology
onlinelibrary.wiley.com/doi/10.1111/...

@hswapnil.medsky.socialOct 8, 2026, 9:37 AM

I haven’t seen that reported automatically!
Agree it’s utility is quite limited
#NephSky

@edgarvlermamd.medsky.networkOct 7, 2026, 12:53 PM

C3G Glomerulopathy: Mechanistic Targets 🎯 of Potential Novel Therapies from @kdigo.org
#Nephpearls #NephSky

👉 kdigo.org/infographics/

@edgarvlermamd.medsky.networkOct 7, 2026, 12:41 PM

IgA Nephropathy #IgAN: Pathophysiology and Mechanistic Targets 🎯 of Potential Novel Therapies from @kdigo.org
#Nephpearls #NephSky

👉 kdigo.org/infographics/

@kidneyint.bsky.socialOct 6, 2026, 5:53 PM

Automated chemiluminescence immunoassay for the detection of anti-nephrin autoantibodies

doi.org/10.1016/j.kint.2026.07.036

#NephSky #MedSky #FSGS #focalsegmentalglomerulosclerosis #PedsNeph #pediatricnephrology

@kidneyint.bsky.socialOct 6, 2026, 5:49 PM

The Renal Iohexol Clearance Survey examined whether testosterone is a risk factor for age-related measured glomerular filtration rate decline in males

doi.org/10.1016/j.kint.2026.07.030

#NephSky #MedSky #OpenAccess #CKD #chronickidneydisease #sexhormones #GFR @uitnorgesarktiske.bsky.social

@kidneyint.bsky.socialOct 6, 2026, 5:46 PM

A randomized cross-over trial of pre-and post-filter #hemodiafiltration modalities in children on maintenance #dialysis -- effects on solute removal and blood pressure

doi.org/10.1016/j.kint.2026.07.032

#NephSky #MedSky #OpenAccess #PedsNeph #HDP @erknet.bsky.social @uclchildhealth.bsky.social

@kidneyint.bsky.socialOct 6, 2026, 5:21 PM

Resident immune cell neighborhoods associate with protein kinase pRIPK3 and fatty acid ligase FACL4 expression during cell injury in ANCA associated vasculitis and #lupusnephritis

doi.org/10.1016/j.kint.2026.07.031

#NephSky #MedSky #OpenAccess #glomerulardisease @yaleschoolofmed.bsky.social #AAV

@kidneyint.bsky.socialOct 6, 2026, 5:13 PM

Asia-Pacific summit on the implementation of clinical practice guidelines on #diabetes and blood pressure management in #chronickidneydisease: a Kidney Disease: Improving Global Outcomes ( #KDIGO) summit report

doi.org/10.1016/j.kint.2026.07.027

#NephSky #MedSky #OpenAccess #CKD #bloodpressure

@edgarvlermamd.medsky.networkOct 4, 2026, 5:58 PM

Select RCTs, informing current management strategies for patients with SA-AKI
#Nephpearls #AKIinICU #NephJC #NephSky

👉 shop.lww.com/Handbook-of-...

@edgarvlermamd.medsky.networkOct 4, 2026, 4:52 PM

Sepsis is a syndrome defined by organ dysfunction because of a dysregulated host response to infection
#Nephpearls #AKIinICU #NephSky

📌 Septic shock is a subset of sepsis defined by hypotension requiring vasopressors to maintain an MAP >/= 65 mm Hg and serum lactate >2 mmol/L after resuscitation

@hswapnil.medsky.socialOct 4, 2026, 12:22 AM

That’s I am waiting for H4RT to be published to be convinced one way or the other for HDF

#NephSky

@nephroseeker.medsky.socialOct 3, 2026, 9:21 PM

8/ Future trials must fix the usual pitfalls:
🚩 Phenotype enrichment (LVH, high K gradient, volume overload)
🚩 Blinded adjudication
🚩Explicit competing-risk modeling
🚩Patient burden metrics
#Nephsky

@nephroseeker.medsky.socialOct 3, 2026, 9:21 PM

Dialysis adequacy MUST move beyond urea kinetics, and some of us have stated this for years.

🫀The dominant threat is cardiovascular stress: volumes, electrolytes, arrhythmia, LV load, inflammation... Kt/V is not enough #Nephsky

academic.oup.com/ndt/advance-...

@coenneli.bsky.socialOct 3, 2026, 5:08 PM

Short-term effects of an SGLT2 inhibitor on divalent ions in autosomal dominant polycystic kidney disease: a randomized crossover trial

I supported some stats, so thank you to everybody involved for this study, now in @ckj-era.bsky.social!

#Science
#WomenInSTEM
#NephSky

👉 doi.org/10.1093/ckj/...

ABSTRACT Background Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a cornerstone of chronic kidney disease (CKD) therapy, reducing disease progression, cardiovascular events, and mortality. Autosomal dominant polycystic kidney disease (ADPKD) patients were excluded from major trials, and data on electrolyte handling with SGLT2 inhibitors, in combination with tolvaptan, are lacking. Methods SIDIA was a randomized, double-blind, placebo-controlled, two-period crossover trial in 15 adults with ADPKD (mean eGFR 68 mL/min/1.73 m²; median age 43 years). Participants received empagliflozin 10 mg or placebo for 14 days, separated by a two-week washout. The primary endpoint was 24-hour urinary and fractional excretion of phosphate, calcium, and magnesium. Exploratory secondary endpoints included markers of kidney stone propensity, inflammation, vitamin D metabolism, and tolerability. Treatment effects were estimated using generalized linear mixed models. Given the small sample size, analyses were exploratory and focused on effect estimation. Results For the primary endpoint, neither 24-hour urinary nor fractional excretion of phosphate, calcium, or magnesium differed between empagliflozin and placebo. Empagliflozin lowered serum uric acid (–26%), increased serum magnesium (+5.7%) and urinary citrate (+78.6%), and reduced blood pressure (–4/–7 mmHg). An expected decline in eGFR (–7.1%) was observed, with no major short-term safety signals observed. Copeptin levels increased with empagliflozin (+26%). Conclusions In this exploratory mechanistic trial, no substantial short-term difference in urinary or fractional excretion of divalent ions were detected with empagliflozin. The observed changes in serum magnesium, urinary citrate, uric acid, and copeptin are hypothesis-generating and require confirmation in larger, longer-term studies.
@nephspace.bsky.socialOct 3, 2026, 3:53 PM

Want to keep up with nephrology, but end up doomscrolling instead? 🎧

NephSpace makes the nutritious stuff as easy as the scroll: the week's kidney research and news in one place, as lively episodes for the couch, the run or the commute.

2-minute trailer: nephspace.com

#NephSky #MedSky #RenalSky

Load more